Drug Interactions between aminolevulinic acid and Septra
This report displays the potential drug interactions for the following 2 drugs:
- aminolevulinic acid
- Septra (sulfamethoxazole/trimethoprim)
Interactions between your drugs
sulfamethoxazole aminolevulinic acid
Applies to: Septra (sulfamethoxazole / trimethoprim) and aminolevulinic acid
GENERALLY AVOID: Patients exposed to photosensitizing agents around the same time as oral aminolevulinic acid may be at an increased risk of a phototoxic skin reaction (severe sunburn). These agents have each been individually associated with photosensitivity reactions and may have additive effects when used together. Medicinal products with known phototoxic or photoallergic potential include, but are not limited to, hypericin-containing products (e.g., St. John's Wort), griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides, quinolones, tetracyclines, and topical aminolevulinate preparations. There is one case report of a severe sunburn lasting for 5 days in a patient who used oral aminolevulinic acid concurrently with a hypericin extract.
MANAGEMENT: Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John's wort) and topical preparations containing aminolevulinic acid should be avoided for 24 hours before and after oral administration of aminolevulinic acid. Some authorities recommend avoiding exposure to any photosensitizing agent for up to 2 weeks after oral administration of aminolevulinic acid. Patients should also avoid exposure of the eyes and skin to sunlight and bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 48 hours after treatment.
References (6)
- Hoffman GA, Gradl G, Schulz M, Haidinger G, Tanew A, Weber B (2020) "The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature." J Eur Acad Dermatol Venereol, 34, p. 589-600
- Blakely KM, Drucker AM, Rosen CF (2019) "Drug-induced photosensitivity—an update: Culprit drugs, prevention and management." Drug Saf, 42, p. 827-47
- (2023) "Product Information. Gliolan (aminolevulinic acid)." Medac UK
- (2022) "Product Information. Gleolan (aminolevulinic acid)." Medexus pharma Inc
- (2020) "Product Information. Gleolan (aminolevulinic acid)." Medexus Pharmaceuticals Inc.
- (2021) "Product Information. Gliolan (aminolevulinic acid)." Specialised Therapeutics Australia Pty Ltd
Drug and food interactions
sulfamethoxazole food
Applies to: Septra (sulfamethoxazole / trimethoprim)
MONITOR: Two cases have been reported in which patients on sulfamethoxazole-trimethoprim therapy, after consuming beer, reported flushing, heart palpitations, dyspnea, headache, and nausea (disulfiram - alcohol type reactions). First-generation sulfonylureas have been reported to cause facial flushing when administered with alcohol by inhibiting acetaldehyde dehydrogenase and subsequently causing acetaldehyde accumulation. Since sulfamethoxazole is chemically related to first-generation sulfonylureas, a disulfiram-like reaction with products containing sulfamethoxazole is theoretically possible. However, pharmacokinetic/pharmacodynamic data are lacking and in addition, the two reported cases cannot be clearly attributed to the concomitant use of sulfamethoxazole-trimethoprim and alcohol.
MANAGEMENT: Patients should be alerted to the potential for this interaction and although the risk for this interaction is minimal, caution is recommended while taking sulfamethoxazole-trimethoprim concomitantly with alcohol.
References (2)
- Heelon MW, White M (1998) "Disulfiram-cotrimoxazole reaction." Pharmacotherapy, 18, p. 869-70
- Mergenhagen KA, Wattengel BA, Skelly MK, Clark CM, Russo TA (2020) "Fact versus fiction: a review of the evidence behind alcohol and antibiotic interactions." Antimicrob Agents Chemother, 64, e02167-19
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.